StreetAlpha.app
Home › Stocks › NBTX

Nanobiotix S.A. (NBTX)

Healthcare
$27.45
▼ −3.82%
LAST CLOSE · NOV 17

Nanobiotix develops nanoparticle medicines, led by a candidate designed to boost the effect of radiotherapy on cancer tumors. It last closed at $27.45 on Nov 17, down 3.82% on the day. NBTX last reported earnings on Tue, Sep 29, 2026.

AI Auto Pilots
Is NBTX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
EUR 32.6M
Net income
−EUR 24.0M
−73.5% margin
Free cash flow
−EUR 34.0M
−104.2% margin
Operating margin
−33.2%
−EUR 10.8M operating income
Balance sheet
Cash & equivalents
EUR 52.8M
At Dec 31
Shareholder equity
−EUR 84.5M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: EUR 2.6MEUR 2.6MFY2021FY2022: EUR 4.8MEUR 4.8MFY2022FY2023: EUR 36.2MEUR 36.2MFY2023FY2024: −EUR 7.2M−EUR 7.2MFY2024FY2025: EUR 32.6MEUR 32.6MFY2025

From NBTX's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 31). Last 12 months adds up the four latest quarters. Figures are in EUR. Per share figures are left out because the US listing can represent a different number of shares.

Last report
Sep 29
2026 · After the close (AMC)
Reported EPS
-$0.80
vs -$0.48 est. · miss
Year-ago EPS
-$0.13
Same quarter last year
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated NBTX in the past 90 days, not enough for a consensus
Average 12-month target
$64.00
▲ 133.2% upside

Based on 1 analyst who set a price target on NBTX in the past 90 days. The average target is $64.00, with a high of $64.00 and a low of $64.00, compared with the last close of $27.45.

Low $64.00Avg $64.00High $64.00
Blue marker: last close $27.45
Highest target$64.00
Average target$64.00
Lowest target$64.00
Latest rating changes
GuggenheimAssumed coverage
Sep 15Buy$64
Leerink PartnersMaintained
Jun 4Buy$46
DateFirmActionRatingPrice target
Sep 15GuggenheimAssumed coverageBuy$64
Jun 4Leerink PartnersMaintainedBuy$46
Loading…

Technical Analysis

NBTX · as of the Nov 17 close · updated after every close
Moving sideways

The stock is 12% below its 20 day and 9% below its 50 day average. It is 25% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 42). The nearest support is the Pivot S1 at $27.18, and the nearest resistance the Pivot at $27.56.

Short trendNeutral
Long trendBearish
MomentumWeak
StretchNormal
VolatilityHigh, 8.8%/day
Key levels
$57.1452 week high+108.2%
$34.83100 day average+26.9%
$34.77Swing high (Oct 27)+26.7%
$34.39200 day average+25.3%
$30.7120 day average+11.9%
$29.9350 day average+9.0%
$27.83Pivot R1+1.4%
$27.56Pivot+0.4%
$27.45Last close
$27.18Pivot S1−1.0%
$20.70Swing low (Oct 19)−24.6%
$19.1452 week low−30.3%
Indicators
RSI (14)42.17Middle of its rangeNeutral
MACD0.24Below its signal lineBearish
Stochastic19.5Near the bottom of its rangeOversold
ADX (14)18.2No clear trend
Williams %R-98.0Oversold below −80, overbought above −20Oversold
CCI (20)-120.2Oversold below −100, overbought above 100Oversold
Rate of change−3.9%Change over 10 sessionsBearish
ATR (14)$2.42Typical daily range, 8.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for NBTX

What happened before

See how NBTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow NBTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How NBTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in NBTX in the last 90 days.

Loading…

See today’s whale options flow across the market →

NBTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲20 buying vs 9 selling
  • ▲Shares held by funds +9.6%
  • ▲Funds holding +9
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding2819+47.4%
In funds' top 10110.0%
Held by funds–––
New / increased12 / 87 / 6+53.8%
Reduced / sold out6 / 32 / 3+80.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See NBTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NBTX is in one of them and how their past NBTX trades turned out.

NBTX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered NBTX in an article yet. Here's the latest on the wider market.

About Nanobiotix S.A.

Nanobiotix is a biotechnology company based in Paris, France, that develops medicines built on nanoparticles. Its lead candidate, JNJ-1900 (NBTXR3), is designed to increase the effect of radiotherapy on tumors while limiting the dose to surrounding healthy tissue, and it is in clinical trials for several cancer types, mainly head and neck and lung cancer. The company also works on earlier stage platforms meant to help other drugs reach target tissues and to treat neurological conditions. Its main partner for the lead candidate is Johnson & Johnson, and the medicines are aimed at people receiving cancer treatment.

Headquarters
Paris, France